JP5395669B2 - 血液試料中の第ｘａ因子インヒビターの電気化学測定のための方法および装置 - Google Patents
血液試料中の第ｘａ因子インヒビターの電気化学測定のための方法および装置 Download PDFInfo
- Publication number
- JP5395669B2 JP5395669B2 JP2009533745A JP2009533745A JP5395669B2 JP 5395669 B2 JP5395669 B2 JP 5395669B2 JP 2009533745 A JP2009533745 A JP 2009533745A JP 2009533745 A JP2009533745 A JP 2009533745A JP 5395669 B2 JP5395669 B2 JP 5395669B2
- Authority
- JP
- Japan
- Prior art keywords
- factor
- reagent
- activator
- test element
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940123583 Factor Xa inhibitor Drugs 0.000 title claims description 66
- 238000000034 method Methods 0.000 title claims description 60
- 210000004369 blood Anatomy 0.000 title claims description 41
- 239000008280 blood Substances 0.000 title claims description 41
- 238000002848 electrochemical method Methods 0.000 title claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 246
- 108010074860 Factor Xa Proteins 0.000 claims description 120
- 238000012360 testing method Methods 0.000 claims description 104
- 108010014173 Factor X Proteins 0.000 claims description 87
- GONFBOIJNUKKST-UHFFFAOYSA-N 5-ethylsulfanyl-2h-tetrazole Chemical compound CCSC=1N=NNN=1 GONFBOIJNUKKST-UHFFFAOYSA-N 0.000 claims description 63
- 108090000190 Thrombin Proteins 0.000 claims description 62
- 229960004072 thrombin Drugs 0.000 claims description 61
- 238000001514 detection method Methods 0.000 claims description 56
- 238000005259 measurement Methods 0.000 claims description 52
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 46
- 229920000669 heparin Polymers 0.000 claims description 42
- 239000000758 substrate Substances 0.000 claims description 41
- 238000006243 chemical reaction Methods 0.000 claims description 33
- 230000000694 effects Effects 0.000 claims description 32
- 229960002897 heparin Drugs 0.000 claims description 32
- 239000000126 substance Substances 0.000 claims description 32
- 239000012190 activator Substances 0.000 claims description 25
- 230000035602 clotting Effects 0.000 claims description 24
- 206010053567 Coagulopathies Diseases 0.000 claims description 21
- 230000015271 coagulation Effects 0.000 claims description 18
- 238000005345 coagulation Methods 0.000 claims description 18
- 229940127215 low-molecular weight heparin Drugs 0.000 claims description 13
- 239000003055 low molecular weight heparin Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 238000000840 electrochemical analysis Methods 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 5
- 229940123688 Direct Factor Xa inhibitor Drugs 0.000 claims description 3
- 108010000499 Thromboplastin Proteins 0.000 claims description 3
- 102000002262 Thromboplastin Human genes 0.000 claims description 3
- 230000006624 extrinsic pathway Effects 0.000 claims description 3
- 230000006623 intrinsic pathway Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 108010054265 Factor VIIa Proteins 0.000 claims description 2
- 108010071241 Factor XIIa Proteins 0.000 claims description 2
- 229940012414 factor viia Drugs 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims 4
- 239000012491 analyte Substances 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 2
- 230000005611 electricity Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 11
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 11
- 102000009123 Fibrin Human genes 0.000 description 11
- 108010073385 Fibrin Proteins 0.000 description 11
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 11
- 239000003114 blood coagulation factor Substances 0.000 description 11
- 229950003499 fibrin Drugs 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical group NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 9
- 102000004411 Antithrombin III Human genes 0.000 description 9
- 108090000935 Antithrombin III Proteins 0.000 description 9
- 229960005348 antithrombin iii Drugs 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- VJZRBVVLWLEXBB-VROPFNGYSA-N (2s)-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]-1-[2-[(4-methylphenyl)sulfonylamino]acetyl]pyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1S(=O)(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)CCC1 VJZRBVVLWLEXBB-VROPFNGYSA-N 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 108010018472 chromozym TH Proteins 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 238000000691 measurement method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000011981 development test Methods 0.000 description 6
- 229940019332 direct factor xa inhibitors Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 108010094028 Prothrombin Proteins 0.000 description 5
- 102100027378 Prothrombin Human genes 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 239000011888 foil Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229940039716 prothrombin Drugs 0.000 description 5
- 108091006149 Electron carriers Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000002628 heparin derivative Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000006249 magnetic particle Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000002821 viper venom Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000271032 Daboia russelii Species 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- 108090000040 Russellysin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000004082 amperometric method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000000835 electrochemical detection Methods 0.000 description 2
- 229960000610 enoxaparin Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 2
- 229960001318 fondaparinux Drugs 0.000 description 2
- 229910002804 graphite Inorganic materials 0.000 description 2
- 239000010439 graphite Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910000510 noble metal Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000004986 phenylenediamines Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000003998 snake venom Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- OFJRNBWSFXEHSA-UHFFFAOYSA-N 2-(3-amino-1,2-benzoxazol-5-yl)-n-[4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide Chemical compound CN(C)CC1=NC=CN1C(C=C1F)=CC=C1NC(=O)C1=CC(C(F)(F)F)=NN1C1=CC=C(ON=C2N)C2=C1 OFJRNBWSFXEHSA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010079356 FIIa Proteins 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010074105 Factor Va Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000003487 electrochemical reaction Methods 0.000 description 1
- 239000007772 electrode material Substances 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical class [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 description 1
- 229950009478 otamixaban Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229950010535 razaxaban Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010345 tape casting Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000004832 voltammetry Methods 0.000 description 1
- 238000001075 voltammogram Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000007704 wet chemistry method Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Electrochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06123234.4 | 2006-10-31 | ||
| EP06123234A EP1918718A1 (de) | 2006-10-31 | 2006-10-31 | Verfahren und Vorrichtungen zur elektrochemischen Bestimmung von Faktor Xa-Inhibitoren in Blutproben |
| PCT/EP2007/009347 WO2008052718A1 (de) | 2006-10-31 | 2007-10-27 | Verfahren und vorrichtungen zur elektrochemischen bestimmung von faktor xa-inhibitoren in blutproben |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010508499A JP2010508499A (ja) | 2010-03-18 |
| JP2010508499A5 JP2010508499A5 (cg-RX-API-DMAC7.html) | 2010-08-05 |
| JP5395669B2 true JP5395669B2 (ja) | 2014-01-22 |
Family
ID=37633621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009533745A Active JP5395669B2 (ja) | 2006-10-31 | 2007-10-27 | 血液試料中の第ｘａ因子インヒビターの電気化学測定のための方法および装置 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8636894B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1918718A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5395669B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101535498B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2667957C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2444011T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008052718A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2471945A1 (de) * | 2010-12-30 | 2012-07-04 | Siemens Healthcare Diagnostics Products GmbH | Verfahren zur Bestimmung von Inhibitoren der Gerinnung |
| JP5946139B2 (ja) * | 2011-03-16 | 2016-07-05 | 学校法人 芝浦工業大学 | 抗凝固薬測定用センサ |
| EP2818871A1 (en) * | 2013-06-28 | 2014-12-31 | Roche Diagniostics GmbH | Means and methods for universal calibration of anti-Factor Xa tests |
| EP3198272B1 (en) | 2014-09-26 | 2022-04-06 | Abbott Point Of Care, Inc. | Cartridge device identification for coagulation assays in fluid samples |
| EP3197603A1 (en) | 2014-09-26 | 2017-08-02 | Abbott Point of Care Inc. | Cartridge device with segmented fluidics for assaying coagulation in fluid samples |
| EP3197602B1 (en) | 2014-09-26 | 2021-09-01 | Abbott Point Of Care, Inc. | Microfabricated device with micro-environment sensors for assaying coagulation in fluid samples |
| CN106999932A (zh) | 2014-09-26 | 2017-08-01 | 雅培医护站股份有限公司 | 用于流体样本中的凝结测定的具有流体结的盒设备 |
| EP3198281B1 (en) | 2014-09-26 | 2023-01-25 | Abbott Point Of Care, Inc. | Ellagic acid formulations for use in coagulation assays |
| ES2911898T3 (es) | 2014-09-26 | 2022-05-23 | Abbott Point Of Care Inc | Dispositivo de cartucho de canal único para ensayos de coagulación de sangre en muestras de fluidos |
| EP3198280B1 (en) * | 2014-09-26 | 2021-05-26 | Abbott Point Of Care, Inc. | Sensors for assaying coagulation in fluid samples |
| CN104714036B (zh) * | 2015-04-01 | 2016-06-01 | 成都协和生物技术有限责任公司 | 抗凝血酶iii活性测定试剂盒的制备方法 |
| CN105203479A (zh) * | 2015-09-21 | 2015-12-30 | 山东万邦赛诺康生化制药股份有限公司 | 用血凝仪测定肝素或低分子量肝素效价的方法 |
| EP3388838B1 (en) * | 2016-01-29 | 2022-02-16 | Sony Group Corporation | Blood coagulation analysis |
| MX2019004224A (es) * | 2016-10-20 | 2019-06-10 | Universal Biosensors Pty Ltd | Soluciones sin riesgo biologico y metodos para analizadores de prueba. |
| EP3971576B1 (en) | 2020-09-21 | 2025-03-19 | Instrumentation Laboratory Company | Detecting and monitoring oral anticoagulants or intravenous direct thrombin inhibitors in a blood sample |
| CN115032164B (zh) * | 2022-08-10 | 2022-12-06 | 山东省食品药品检验研究院 | 一种肝素钠中是否含有凝血因子Xa直接抑制剂的检测方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI895215A7 (fi) * | 1988-03-03 | 1989-11-02 | Nippon Shoji Kk | Menetelmä antitrombiini III:n biologisen aktiivisuuden määrittämiseksi ja reagenssi sitä varten |
| JP3094165B2 (ja) * | 1990-11-05 | 2000-10-03 | バクスター、ダイアグノスチックス、インコーポレイテッド | 抗凝固剤濃度測定方法 |
| US5308756A (en) * | 1991-11-20 | 1994-05-03 | Baxter Diagnostics Inc. | Protein S chromogenic assay |
| JPH08501153A (ja) * | 1992-09-04 | 1996-02-06 | グラディポール リミテッド | 液体の凝固／溶解を検出する方法および装置 |
| AU689768B2 (en) * | 1993-02-17 | 1998-04-09 | Cardiovascular Diagnostics, Inc. | Dry chemistry cascade immunoassay and affinity assay |
| US5762770A (en) | 1994-02-21 | 1998-06-09 | Boehringer Mannheim Corporation | Electrochemical biosensor test strip |
| EP1384725A3 (en) * | 1994-04-26 | 2007-02-21 | Aventis Pharmaceuticals Inc. | Factor Xa inhibitors |
| NL1006429C2 (nl) * | 1997-06-27 | 1998-12-29 | Univ Maastricht | Werkwijze voor het bepalen van het heparinegehalte. |
| US5997817A (en) | 1997-12-05 | 1999-12-07 | Roche Diagnostics Corporation | Electrochemical biosensor test strip |
| AU5062100A (en) * | 1999-06-14 | 2001-01-02 | Novo Nordisk A/S | Fviia/tf activity inhibiting compounds |
| AU2431800A (en) * | 1999-12-15 | 2001-06-25 | Pentapharm Ag | Hematological assay and reagent |
| US6438498B1 (en) * | 2000-02-10 | 2002-08-20 | I-Stat Corporation | System, method and computer implemented process for assaying coagulation in fluid samples |
| CA2400651A1 (en) * | 2000-02-21 | 2001-08-30 | F. Hoffmann-La Roche Ag | Electrochemical sensor for determining blood clotting, corresponding system for measuring blood clotting and method for determining blood clotting |
| US20030146113A1 (en) * | 2000-02-21 | 2003-08-07 | Volker Unkrig | Electrochemical sensor for determining blood clotting, corresponding system for measuring blood clotting and method for determining blood clotting |
| US7166208B2 (en) | 2004-03-03 | 2007-01-23 | Stephen Eliot Zweig | Apoenzyme reactivation electrochemical detection method and assay |
| US6680177B2 (en) * | 2001-12-07 | 2004-01-20 | Cardiovascular Diagnostics, Inc. | Low molecular weight heparin assay, system and reagent therefor |
| US7579000B2 (en) * | 2002-05-01 | 2009-08-25 | Bayer Schering Pharma Ag | Tissue factor targeted antibodies as anticoagulants |
| WO2005031303A2 (en) * | 2003-09-22 | 2005-04-07 | University Of North Carolina At Chapel Hill | Soluble phospholipids for use in clotting factor assays |
-
2006
- 2006-10-31 EP EP06123234A patent/EP1918718A1/de not_active Ceased
-
2007
- 2007-10-27 WO PCT/EP2007/009347 patent/WO2008052718A1/de not_active Ceased
- 2007-10-27 ES ES07819390.1T patent/ES2444011T3/es active Active
- 2007-10-27 CN CN2007800408199A patent/CN101535498B/zh active Active
- 2007-10-27 JP JP2009533745A patent/JP5395669B2/ja active Active
- 2007-10-27 EP EP07819390.1A patent/EP2079849B1/de active Active
- 2007-10-27 CA CA2667957A patent/CA2667957C/en not_active Expired - Fee Related
-
2009
- 2009-04-29 US US12/432,490 patent/US8636894B2/en active Active
-
2013
- 2013-12-20 US US14/136,769 patent/US9594042B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2667957A1 (en) | 2008-05-08 |
| EP2079849A1 (de) | 2009-07-22 |
| JP2010508499A (ja) | 2010-03-18 |
| CN101535498A (zh) | 2009-09-16 |
| US8636894B2 (en) | 2014-01-28 |
| CN101535498B (zh) | 2012-11-14 |
| US20140106383A1 (en) | 2014-04-17 |
| EP1918718A1 (de) | 2008-05-07 |
| US20090236238A1 (en) | 2009-09-24 |
| CA2667957C (en) | 2013-03-05 |
| ES2444011T3 (es) | 2014-02-21 |
| WO2008052718A1 (de) | 2008-05-08 |
| US9594042B2 (en) | 2017-03-14 |
| HK1137783A1 (en) | 2010-08-06 |
| EP2079849B1 (de) | 2013-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5395669B2 (ja) | 血液試料中の第ｘａ因子インヒビターの電気化学測定のための方法および装置 | |
| KR101854883B1 (ko) | 전기화학적 검출용의 장치 및 방법 | |
| US20040011672A1 (en) | Electrochemical coagulation assay and device | |
| RU2583133C2 (ru) | Система распознавания недостаточного заполнения для биосенсора | |
| JP5122094B2 (ja) | 体液中のタンパク分解酵素を差分決定するシステム | |
| WO2001063271A1 (de) | Elektrochemischer sensor zur bestimmung der blutgerinnung, ein entsprechendes blutgerinnungsmesssystem sowie ein verfahren zur bestimmung der blutgerinnung | |
| JP6853194B2 (ja) | 体液試料中の少なくとも１つの分析物を電気化学的に検出するための方法および試験要素 | |
| Mruthunjaya et al. | Calibration-free electrochemical sensor to monitor factor-Xa inhibitors at the point-of-care anticoagulation therapy | |
| US11262345B2 (en) | Method for measuring glycated protein using interdigitated electrode | |
| HK1137783B (en) | Methods and apparatuses for electrochemical determination of factor xa inhibitors in blood samples | |
| JP2006105615A (ja) | 電気化学的測定方法およびそれを使用した測定装置 | |
| Bahram et al. | Voltammetric determination of dopamine in the presence of ascorbic and uric acids using partial least squares regression: determination of dopamine in human urine and plasma | |
| WO2025132678A1 (en) | Qualitative test for direct oral anticoagulants (doacs) | |
| HK1146839B (en) | Apparatus and method for electrochemical detection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100615 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100615 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130611 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130617 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130917 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131010 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131018 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5395669 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |